Can a diabetes drug help hearts recover after valve surgery?
NCT ID NCT06171802
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tested whether empagliflozin (Jardiance), a diabetes drug, can help the heart recover after aortic valve replacement. 206 patients took either the drug or a placebo for six months. The goal was to see if the drug reduces heart muscle thickness and improves symptoms.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
empagliflozin (Jardiance)
What this could lead to
If it works, this could point toward a way to improve heart healing after valve replacement, potentially reducing the risk of heart failure.
What could go wrong
This is a small, early-phase 4 trial with only 206 patients. The results may not be strong enough to change practice, and empagliflozin may not provide added benefit over standard care.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for AORTIC VALVE STENOSIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
University Hospital of Copenhagen, Rigshospitalet
Copenhagen, 2100, Denmark